The history and results of the National Acute Spinal Cord Injury Studies (NASCIS) are briefly reviewed. The current status of pharmacological therapy for acute spinal cord injury and future prospects are also summarized.
The possibility of pharmacologically treat ing acute spinal cord injury, particularly the post injury destruction of neurons by ox ygen-free radical induced lipid peroxida tion, has been suspected for many years. 1 Several pharmacological agents have been examined in a variety of animal models but with conflicting results. Differences in animal models, injury models, drug dosing protocols, methods for evaluating neuro logical recovery, together with the small number of animals usually studied, prevent unequivocal conclusions being drawn from most of this literature.
Methylprednisolone is a notable excep tion, being investigated in one of the most scientifically valid series of animal experi ments, starting with low doses in the order of 1.0 mg/kg, and then later doses of 15 and 30 mg/kg. This work has recently been reviewed by Hall. 2 In 1977 the National Acute Spinal Cord Injury Study (NASCIS) was established to empirically investigate, in multicenter ran domized controlled trials, the safety and efficacy of pharmacological agents of poten tial value in the early treatment of acute spinal cord injury. After a 2 year feasibility study to ensure that different medical cent ers could follow common study protocols the first study (NASCIS 1) was launched. NASCIS 1 compared 2 doses of methylpred nisolone: the low dose consisted of a 15 minute bolus of 0.1 gm followed by 10 daily doses of 0.1 g administered by i. v. push (25 mg every 6 hours). The high dose regimen was exactly the same except for a tenfold increase in the dose. A total of 330 patients were randomized to the trial; however, no significant difference in neuro logical recovery at 6 weeks or 6 months3 or one year4 after injury was observed.
In 1985, NASCIS 2 was started. Whereas the earlier trial had not included a placebo group, because of the existing widespread use of (very low doses of) steroids and for fear of litigation by some of the participating surgeons, the results of NASCIS 1 provided a rationale for subsequently using a placebo comparison group. In view of the promising animal work with the 30 mg/kg dose of methylprednisolone5 this dose became one of the treatment arms under study. A series of animal studies using naloxone6 led us to include this as a third treatment arm. The treatment arms for NASCIS 2 are summar ized in Table 1 .
In addition to the primary study hypo theses concerning drug efficacy and safety, the study hypothesized that patients treated relatively quickly after injury would be more likely to exhibit any therapeutic effects of drug therapy than those treated later. Further, it was postulated that any evidence of neurological effect on recovery would be seen primarily in those patients who were defined as being incomplete (ie with either some sensory or motor preservation below the level of lesion at the time of the initial examination). In May of 1990, the results of the 6 week and 6 month follow up examinations of the 487 people randomized in NASCIS 2 were published. 7 The study demonstrated that patients treated with methylprednisolone, within 8 hours of injury, showed signifi cantly greater neurological recovery than those treated with placebo. These results have recently been shown to essentially persist one year after injury. 8 While nalox one-treated patients also generally showed greater neurological recovery than placebo, these differences could not be distinguished from chance in the analyses done to date in this study. Naloxone is not considered further in the present report. A summary of the results of the methyl prednisolone and placebo comparisons for NASCIS 2 patients, treated within 8 hours of injury, is presented in Figure 1 . Here the neurological change score, reported in the earlier more detailed statistical analyses of these data7 , 8 , is reported as a function of the neurological deficit observed in the emergency room. It reflects what propor tion of the initial neurological loss, observed in the emergency room, has been recovered at each follow up period. Thus:
Normal score -emergency room neurological score Figure 1 , upper panel, shows the relative recovery in motor function of the placebo and methylprednisolone-treated patients 6 weeks, 6 months and one year after injury. At 6 weeks, the placebo-treated patients recovered 11.6% of their lost neurological function compared with 18.6% of methyl prednisolone-treated patients. At 6 months, placebo-treated patients had recovered 19.7% of their initially lost motor function compared with 28.6% in the methylpredni solone group. At one year, the respective recovery rates were 21.4% and 30.2%. The asterisks reflect significance testing for these comparisons from the analyses of variance reported previously. 7 , 8
The lower 2 panels of Figure 1 show the data for pinprick and light touch sensation. A similar pattern of results is observed to that seen for motor function, although fewer comparisons achieve nominal statistical sig nificance reflecting generally greater varia bility in the sensory outcomes. Figure 2 shows the recovery of patients grouped by whether they were neurologic ally complete or incomplete on their emergency room examination.
The upper panel of Figure 2 indicates that methylprednisolone-treated patients who had neurologically complete injuries in the emergency room (with no motor or sensory function below level of lesion) recover significantly more of their motor function if treated with methylprednisolone within 8 hours of injury compared with placebo. This enhanced recovery is also seen at 6 months and one year. As expected, overall recovery in the incomplete patients is considerably more than the complete patients, irrespec tive of treatment. The neurologically incom plete patients also recovered significantly more motor function if treated with me thylprednisolone. Similar results are ob served for recovery of pinprick and light touch sensation.
Current status of pharmacological therapy
There have been no empirical studies to chance of benefit; however, there are no human data to address this. There is no evidence that higher doses of methylprednisolone would be effective, and in cat studies, a 60 mg/kg dose proved ineffective. NASCIS 1 and other animal studies indicate that lower doses of methyl prednisolone are unlikely to be effective. Nor can it be assumed that other steroids used for CNS trauma, will have the same neurological effects as methylprednisolone, particularly given the proposed mechanisms of lipid peroxidation inhibition thought to induce its effect. The importance of limiting treatment by methylprednisolone to pati ents whose treatment can begin within 8 hours of injury (which should be possible in virtually all patients) is emphasized by evidence in the NASCIS 2 data that patients given methylprednisolone have generally worse neurological outcomes than patients receiving placebo. 8 A number of . fa � tors which may explain why delayed adml �l1 S � r � tion of methylprednisolone could l ? hlblt neurolo � ical recovery have been revIewed by Hall.
Future prospects for pharmacological therapy
The NASCIS 2 results have provided, in normal clinical settings, the first support for the hypothesis that a pharmacological agent can reduce the permanent neurological dis ability that usually follows an acute spinal cord injury. In so doing, the study has validated over 20 years of experimental investigation of the same general hypothe sis. The precise mechanisms by which neurological preservation occurs have been widely discussed2 , 10 but remain uncertain. It is likely that several beneficial effects occur.
The NASCIS studies also point to the necessity of evaluating pharmacological therapy under the rigorous conditions of randomized controlled trials.l1 Not only do therapeutic regimens harbor the potential for serious side effects but the modest degree of recovery achieved is only likely to be reliably observed in relatively large studies. Spinal cord injury is a very hetero geneous condition and the high de w� e of variability exhibited in the charactenstlcs of the injury, and recovery from it, dema�d large samples of patients to document vahd pharmacological effects.
The NASCIS group of investigators are presently conducting a third trial in whic . h the lipid peroxidation inhi?i � ion hyp ? th � SlS is being explicitly tested. LIpId peroxldahon almost certainly continues in the spinal cord for a period longer than 24 hours; th � s, it is theoretically possible that by extendmg the 24-hour NASCIS protocol to 48 hours, greater neurological recov . ery will be achieved. We are also studymg the thera peutic effects of Tirilazad, . a . dru � � it� especially potent lipid peroxldahon mhlbl tion properties,12 also administ � red for . 48 hours. Tirilazad lacks any corhcosterOIdal properties; thus, any complications . which the 48-hour regimen of methylpredmsolone may incur are unlikely to be seen with Tirilazad. The specific treatments under study in NASCIS 3 are: (1) MPSS 30 mg/kg 15 minute bolus followed by 24 hour MPSS at 5.4 mg/kg/hr; (2) MPSS 30 mgjkg 15 bolus followed by 48 hour MPSS at 5. 4 mgjkg/hr; and (3) MPSS 30 mg/kg 15 bolus followed by 48 hour Tirilazad at 2.5 mg/kg every 6 hours.
In a recent report, 16 patients who re ceived GM-l ganglioside were compared to 18 patients receiving placebo.13 This was a Phase 1 randomized trial designed to test GM-l for safety. However, improved neurological function was observed in the GM-l patients on both their Frankel grades and motor scores one year after injury. This small study provides strong support for conducting a Phase 3 clinical trial of the efficacy of GM-l but cannot itself be used � s evidence for the routine use of GM-l m clinical practice. It is of particular intere � t that unlike NASCIS 2, where methylpredm sol one treatment had to start within 8 hours to be efficacious and continued for only 24 hours, GM-l was started within 48 hours (range 19-72) and was administered for an average of 26 days (range 18-32). Should GM-l be found to be effective in a larger trial it will suggest alternative biological mechanisms of recovery, and the possibility of using different pharmacological therapies for treatment both in the early phase of injury and during the later management of the patient.
When Paraplegia was founded 30 years ago, there was no prospect of reducing or reversing paralysis resulting from acute spinal cord injury. In the intervening years, we have seen the evolution of the animal model, numerous experimental studies of pharmacological agents, creation of multi center randomized trials to evaluate drug therapy, demonstration of the efficacy and safety of· one therapy -high dose methyl prednisolone-in a human tr . ial, and the promise of additional therapIes presently being studied.
